来源：格隆汇APP 格隆汇2月27日｜港股主要指数午后拉升，其中，恒生指数涨超1%，恒生科技指数涨近1%，国企指数 涨0.74%。恒生指数成分股中，新鸿基地产涨超6%领涨，药明生物涨超4%，石药集团、药明康德涨超 3%，网易、携程、腾讯、泡泡玛特、蒙牛乳业、中通快递涨超2%。 | 代码 | 名称 | | 涨跌幅 √ | 年初至今涨跌 | 总市值 | | --- | --- | --- | --- | --- | --- | | 00016 | 新鸿基地产 | (0) | 6.02% | 52.59% | 4187.29 Z | | 02269 | 药明生物 | | 4.81% | 27.61% | 1659.98亿 | | 01093 | 石药集团 | | 3.67% | 17.32% | 1139.57亿 | | 02359 | 药明康德 | | 3.04% | 20.36% | 3544.7 Z | | 099999 | 网易-S | | 2.74% | -16.22% | 5692.45 Z | | 09961 | 携程集团-S | | 2.60% | -25.85% | 2685亿 | | 00700 ...

siRNA行业先驱Alnylam开发的GalNAc肝内递送凭借递送效率极高、特异性强以及作用持久等优势，已 成为肝递送的"标准答案"，其他海外巨头如Arrowhead和Dicerna等针对PCSK9、AGT、Lp(a)以及ApoC3 等心血管常见靶点的siRNA药物已进入临床后期或商业化的收获期，而针对肌肉、神经系统以及眼部等 肝外器官目前仍处于研发早期阶段，目前Alnylam的C16递送平台已在CNS领域、Arrowhead的TRiM平 台在脂肪组织领域初步展现潜力，未来新靶点的发现与肝外递送平台将成为竞争的核心要点。 智通财经APP获悉，中邮证券发布研报称，siRNA药物可精准沉默致病蛋白，优势显著，递送系统为核 心技术。海外巨头基于GalNAc肝递送平台，针对心血管靶点的药物已进入收获期。国内企业百花齐 放，成为全球重要参与者，与MNC合作频发。 中邮证券主要观点如下： siRNA药物机制优势突出，递送为核心技术 相较于传统小分子和生物药，siRNA药物为代表的核酸疗法可精准沉默致病蛋白，高效降解且作用时间 长，目前已成为新药开发热门方向。技术层面主要包括修饰和递送，其中递送为核心技术，肝外递送是 目前 ...

证券研究报告 ➢ siRNA药物机制优势突出，递送为核心技术 相较于传统小分子和生物药，siRNA药物为代表的核酸疗法可精准沉默致病蛋白，高效降解且作用时间长，目前已成为新药开发热门方向。 技术层面主要包括修饰和递送，其中递送为核心技术，肝外递送是目前的突破重心，技术路径包括LNP、抗体、肽类以及VLP递送，各有优劣， 其中AOC发展稍快。 ➢ 海外巨头渐入收获期，静待肝外递送POC 黎明已至，国产争先 ——siRNA药物行业深度报告 行业投资评级：强大于市|维持 盛丽华/陈灿 中邮证券研究所 医药生物团队 中邮证券 1 1 发布时间：2026-02-27 投资要点 siRNA行业先驱Alnylam开发的GalNAc肝内递送凭借递送效率极高、特异性强以及作用持久等优势，已成为肝递送的"标准答案"，其他海 外巨头如Arrowhead和Dicerna等针对PCSK9、AGT、Lp(a)以及ApoC3等心血管常见靶点的siRNA药物已进入临床后期或商业化的收获期，而 针对肌肉、神经系统以及眼部等肝外器官目前仍处于研发早期阶段，目前Alnylam的C16递送平台已在CNS领域、Arrowhead的TRiM平台在脂 肪 ...

Core Viewpoint - The Hong Kong Dividend ETF (ICBC, 159691) has experienced significant net redemptions, indicating a trend of outflows from the fund, which may reflect investor sentiment and market conditions [1][2]. Group 1: Fund Performance - On February 26, the Hong Kong Dividend ETF (ICBC, 159691) faced a net redemption of 69.2 million yuan, ranking 4th out of 217 in cross-border ETF net outflows for the day [1]. - Over the past five days, the fund has seen net redemptions totaling 123 million yuan, ranking 2nd out of 217 [1]. - The fund's total size as of February 26 is 8.549 billion yuan, down from 8.78 billion yuan the previous day, with the outflow representing 0.79% of the prior day's size [1]. Group 2: Fund Details - The Hong Kong Dividend ETF (ICBC, 159691) was established on March 30, 2023, with an annual management fee of 0.45% and a custody fee of 0.07% [2]. - As of February 26, the fund has 6.134 billion shares outstanding, a decrease of 6.06% from 6.53 billion shares on December 31, 2025, while the fund's size has increased by 1.35% during the same period [2]. Group 3: Trading Activity - The cumulative trading amount for the Hong Kong Dividend ETF over the last 20 trading days is 6.993 billion yuan, with an average daily trading amount of 350 million yuan [2]. - Year-to-date, the fund has recorded a cumulative trading amount of 10.928 billion yuan over 33 trading days, averaging 331 million yuan per day [2]. Group 4: Fund Holdings - The current fund managers are Zhao Xu and Jiao Wenlong, both managing the fund since February 5, 2026, with a return of 1.12% during their tenure [3]. - Major holdings in the fund include China National Offshore Oil Corporation (14.55%), China Shenhua Energy (9.65%), and China Pacific Insurance (8.90%), among others, with significant market values [3].

创新药龙头重磅业绩利好！百济神州2月26日发布2025年度业绩快报，全年营收382.05亿元，同比增 40.4%；归母净利润14.22亿元，实现扭亏为盈。 值得一提的是，这是这家创新药龙头公司首次实现年度盈利，也是中国创新药企全球化发展的重要里程 碑。 公告显示，百济神州业绩增长得益于核心产品放量，2025年百悦泽全球销售额280.67亿元，同比增长 48.8%。此外，公司多款候选药物进入临床关键阶段，百悦达在中国获批上市，BGB-B2033获FDA快速 通道资格认定。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调两个季度，长期看，较多优质标的估值性价比 明显，当前位置建议加大关注。* 低位埋伏创新药机遇，借道ETF效率更高！ 投纯正创新药，认准T+0利器——港股通创新药ETF（520880）及其场外联接基金（025221），100%布 局创新药研发类公司，前十大权重股占比超七成，龙头属性突出。 降低波动 | 项目 | 本报告期 | 上年同期 | 增减变动幅度(%) | | --- | --- | --- ...

Core Insights - The introduction of PD-1 inhibitors in 2014 marked a significant turning point in the fight against cancer, with Bristol-Myers Squibb's Opdivo and Merck's Keytruda leading the charge in immunotherapy [1][3] - The competition between Opdivo and Keytruda has evolved over the years, with Keytruda ultimately becoming the top-selling drug globally by 2024 [21][22] Historical Context - The history of cancer immunotherapy began with William Coley's discovery in the late 19th century, which was followed by a long period of stagnation until the late 20th century when key immune cells were identified [4] - The discoveries of James Allison and Tasuku Honjo regarding CTLA-4 and PD-1, respectively, laid the groundwork for the development of PD-1 inhibitors [5][10] Drug Development - Opdivo was developed with strong backing from Bristol-Myers Squibb after acquiring Medarex in 2009, leading to its approval in Japan in 2014 [12] - Keytruda's development faced initial setbacks but was revitalized by Merck's strategic decision to conduct an unprecedented "super I phase" trial, leading to its approval shortly after Opdivo [14][15][16] Market Dynamics - In 2016, a critical competition occurred between Opdivo and Keytruda in the non-small cell lung cancer (NSCLC) market, which is the largest segment in oncology [17] - BMS's failure in the CheckMate-026 trial led to a significant drop in Opdivo's market position, while Merck's more selective approach in the KEYNOTE-024 trial resulted in Keytruda's success [18][19][20] Sales Performance - By 2024, Keytruda's sales reached $29.5 billion, marking an 18% increase and solidifying its position as the top-selling drug globally [21] - Opdivo, while still a major player, saw its sales decline but remained above the $10 billion mark, maintaining its status as a heavyweight in the market [22][23] Competitive Landscape - The global PD-1 inhibitor market is highly competitive, with 527 candidates in development as of early 2025, including 20 approved drugs [26][29] - In China, the market is characterized by intense competition among local manufacturers, with significant price reductions due to national healthcare negotiations [30][31] Future Outlook - Keytruda's core patent is expected to expire in 2028, potentially leading to a significant drop in sales as biosimilars enter the market [32] - A new challenger, Ivonescimab, has shown superior efficacy compared to Keytruda in clinical trials, indicating a shift towards dual-target therapies in cancer treatment [33][35]

2月27日，港股三大股指集体高开，其中恒生指数涨0.25%，报26447.05点，恒生科技指数涨0.15%，报 5117.24点，国企指数涨0.04%，报8817.53点，红筹指数跌0.06%，报4409.07点； 盘面上，大型科技股多数走高，腾讯控股跌0.29%，京东集团涨0.96%，小米集团跌0.8%，网易涨 0.11%，美团涨0.68%，哔哩哔哩涨0.37%；生物医药（核心股）板块回暖，再鼎医药绩后涨4.90%，药 明生物涨4.86%；机器人（核心股）概念股活跃，商汤涨超4%；有色金属（核心股）板块高开，紫金矿 业涨超1%；芯片股普跌，兆易创新跌超4%；汽车股走弱，蔚来跌近1%。 企业动态：业绩亮眼，动作频频 中慧生物-B（02627.HK）2025财年营收4.46亿元至人民币4.93亿元，同比增加约71.8%至89.9%，但净亏 损1.57亿元至人民币1.97亿元。 百度集团-SW（09888.HK）发布2025年第四季度及全年业绩，第四季度总收入327亿元，环比增长5%， NON - GAAP净利润39亿元。智能云基础设施收入达58亿元，AI高性能计算设施收入的订阅收入同比增 长143%，无人车服务 ...

Group 1: China Ping An - The core strategy of China Ping An is "comprehensive finance + medical care and elderly care," which aims to create a new value growth pole through a "product + service" model, leading to long-term stable profit growth [3][4] - The report suggests that the current market valuation of China Ping An is low, with a PEV of 0.75, and recommends a target market value of 1.6 trillion yuan, corresponding to a target price of 88.53 yuan per share [3][4] - The aging population in China and the increasing importance of commercial health insurance in medical payments are expected to enhance the effectiveness of the "product + service" model, positioning it as a new growth driver for the company [3][4] Group 2: Steel Research High Temperature Alloy - Steel Research High Temperature Alloy is a leading company in the high-temperature alloy sector, benefiting from strong demand in the aerospace industry and the trend towards technological self-sufficiency [5][6] - The company is expected to achieve steady growth in net profit, with forecasts of 132 million yuan, 152 million yuan, and 172 million yuan for 2025 to 2027, respectively [5][6] - The report highlights the resilience of the high-temperature alloy industry, driven by increasing defense budgets and the upgrade of aerospace equipment, which supports long-term demand [6][7] Group 3: CSPC Pharmaceutical Group - CSPC Pharmaceutical Group is recognized for its strong innovation capabilities, with a focus on oncology and chronic disease treatment pipelines, and has established an international business development ecosystem [8][9] - The company has entered a strategic collaboration with AstraZeneca to develop innovative long-acting peptide drugs, which is expected to generate significant revenue potential [9][10] - The report predicts EPS growth of 48%, 36%, and -7% for 2025 to 2027, with a target price of 16.58 HKD per share [8][9] Group 4: Real Estate Market - The real estate market in China is currently in a deep adjustment phase, with only 19% of cities showing signs of bottoming out as of Q4 2025 [18][19] - New home prices are experiencing significant fluctuations, particularly in first-tier cities, while second-hand home prices are generally declining [19][20] - The report indicates that the inventory clearance cycle is extending, with first-tier cities reaching 19-28 months and some second-tier cities exceeding 38 months [20] Group 5: Robotics and Automation - The company is actively expanding into the humanoid robotics sector, with new product launches expected to drive growth [21][22] - The report forecasts EPS of 1.14, 1.47, and 1.83 yuan for 2025 to 2027, with a target price of 147.00 yuan per share [21][22] - The company is leveraging its expertise in micro-drive systems to enhance its competitive position in the robotics market [22][23] Group 6: Energy Storage Sector - The energy storage sector is anticipated to see significant growth, with the introduction of capacity pricing mechanisms in provinces like Qinghai [36][37] - The report suggests that the demand for energy storage systems and batteries will increase, recommending several key stocks in this sector [36][37] - The expected growth rate for energy storage demand in 2026 is projected to be around 50% [38]

写在文章前的声明：在本文之前的说明：本文中所列的投资信息，只是一个对基金资产净值进行排行的客观描述，并无主观倾向性，也不是投资建议，纯属 娱乐性质。 一顿操作猛如虎，基金净值已更新，谁是基金中的王者，谁又垫底，请看数据： | 基金简称 PK | | | YANNEWSGH FRANCE AND | | | --- | --- | --- | --- | --- | | 1 | 华泰柏瑞中 ... C | 2.7528 | 6.04% | 8 | | | 019455 | 2026-2-26 | | | | 2 | 华泰柏瑞中 ... A | 2.7691 | 6.03% | 8 | | | 019454 | 2026-2-26 | | | | 3 | 华泰柏瑞中韩 ... l | 2.7662 | 6.03% | 8 | | | 022681 | 2026-2-26 | | | | 4 | 广发利鑫混合C | 3.0650 | 5.44% | | | | 011172 | 2026-2-26 | | | | 5 | 广发利鑫混合A | 3.1270 | 5.43% | 8 | | | 002446 | 202 ...

石药集团(01093)发布公告，于2026年2月25日，卖方石药创新制药股份有限公司(本公司非全资附属公 司，(股份代号：300765))与买方石药控股集团有限公司订立股权转让协议，内容有关买卖目标公司北京 国新汇金股份（300368）有限公司的30.0704%股权，代价为人民币2.3亿元。于出售事项完成后，卖方 及本集团将不再持有目标公司的任何股权。 目标公司主要从事全媒体传播业务平台的运营，该业务并不属于卖方的核心业务。出售事项乃基于对卖 方实际发展状况的全面考量。预期出售事项将有助于优化卖方的资源配置及财务结构;同时，此举可使 卖方专注于核心业务并降低营运风险，从而实现高质量发展，亦对本集团整体有利。 ...